PANACEA LIFE SCIENCES HOLDINGS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PANACEA LIFE SCIENCES HOLDINGS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $2.06M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $9.02M | Mar 31, 2022 |
| FY2020 | Mar 31, 2020 | $836.0K | Apr 23, 2021 |
| FY2020 | Dec 31, 2019 | $345.7K | Apr 23, 2021 |
| FY2020 | Sep 30, 2019 | $60.2K | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | $0 | May 22, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 2, 2018 |
| FY2015 | Dec 31, 2015 | $213 | Feb 29, 2016 |
| FY2015 | Dec 31, 2014 | $852 | Feb 29, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.38M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $1.63M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.06M | Mar 30, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.12M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $396.5K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $540.6K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.00M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.70M) | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | $0 | May 22, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($8.02M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($9.14M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($4.78M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($5.23M) | Mar 31, 2022 |
| FY2020 | Mar 31, 2020 | ($2.82M) | Apr 23, 2021 |
| FY2020 | Dec 31, 2019 | ($10.02M) | Apr 23, 2021 |
| FY2020 | Sep 30, 2019 | ($2.03M) | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | ($4.34M) | May 22, 2020 |
| FY2018 | Dec 31, 2017 | ($3.86M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($1.60M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($5.55M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($5.65M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.94M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($5.26M) | Mar 31, 2022 |
| FY2020 | Mar 31, 2020 | ($2.63M) | Apr 23, 2021 |
| FY2020 | Dec 31, 2019 | ($10.67M) | Apr 23, 2021 |
| FY2020 | Sep 30, 2019 | ($2.02M) | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | ($2.44M) | May 22, 2020 |
| FY2018 | Dec 31, 2017 | ($3.12M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($1.60M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Apr 23, 2021 |
| FY2020 | Dec 31, 2019 | $22.1K | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | $300.0K | May 22, 2020 |
| FY2018 | Dec 31, 2017 | $356.1K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $369.3K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $77.3K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $58.3K | Feb 29, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($1.52M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($2.40M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.92M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($7.65M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($5.75M) | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | ($465.8K) | May 22, 2020 |
| FY2018 | Dec 31, 2017 | ($1.23M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($891.0K) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($640.0K) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | ($399.7K) | Feb 29, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $65.3K | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $243.8K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $162.9K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.20M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $541.2K | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | $0 | May 22, 2020 |
| FY2016 | Dec 31, 2016 | ($1.3K) | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $0 | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $6.0K | Feb 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $17.98M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $19.49M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $23.78M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $31.36M | Mar 31, 2022 |
| FY2020 | Mar 31, 2020 | $6.75M | Apr 23, 2021 |
| FY2020 | Dec 31, 2019 | $8.02M | Apr 23, 2021 |
| FY2020 | Sep 30, 2019 | $9.59M | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | $14.3K | May 22, 2020 |
| FY2018 | Dec 31, 2017 | $172.7K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $2.13M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $26.27M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $21.63M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $16.68M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $24.65M | Mar 31, 2022 |
| FY2020 | Mar 31, 2020 | $4.95M | Apr 23, 2021 |
| FY2020 | Dec 31, 2019 | $4.13M | Apr 23, 2021 |
| FY2020 | Sep 30, 2019 | $2.11M | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | $3.44M | May 22, 2020 |
| FY2018 | Dec 31, 2017 | $2.39M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $625.0K | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($8.29M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($2.14M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.10M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.71M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $11.94M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | ($3.42M) | May 22, 2020 |
| FY2018 | Dec 31, 2017 | ($2.22M) | Mar 29, 2019 |
| FY2018 | Dec 31, 2016 | $1.50M | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | ($93.3K) | Apr 2, 2018 |
| FY2016 | Dec 31, 2014 | $45.8K | Mar 31, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.01M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $2.19M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.19M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.19M | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($33.92M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($25.91M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($16.77M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($11.98M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($20.92M) | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | ($10.54M) | May 22, 2020 |
| FY2018 | Dec 31, 2017 | ($6.20M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($2.34M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($737.0K) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | ($379.0K) | Feb 29, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $100.9K | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $7.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $19.8K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $84.4K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $18.4K | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | $2.0K | May 22, 2020 |
| FY2018 | Dec 31, 2017 | $161.2K | Mar 29, 2019 |
| FY2018 | Dec 31, 2016 | $1.06M | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | $0 | Apr 2, 2018 |
| FY2016 | Dec 31, 2014 | $41.7K | Mar 31, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $335.5K | Apr 23, 2021 |
| FY2019 | Dec 31, 2019 | $185.9K | May 22, 2020 |
| FY2019 | Dec 31, 2018 | $591.8K | May 22, 2020 |
| FY2018 | Dec 31, 2017 | $57.8K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 17.65M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | 14.97M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 14.07M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 16.92M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 43.82M | Apr 23, 2021 |
| FY2019 | Dec 31, 2018 | 6.23M | May 22, 2020 |
| FY2018 | Dec 31, 2017 | 4.38M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 34.07M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 515,290 | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | 15.14M | Feb 29, 2016 |